Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 05.

392P - A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer

Date

03 Dec 2022

Session

Poster viewing 05.

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Jinji Yang

Citation

Annals of Oncology (2022) 33 (suppl_9): S1560-S1597. 10.1016/annonc/annonc1134

Authors

J. Yang1, J. Zhou2, M. li3, Z. Zhang4, Y. Cheng5, D.H. Chu6, H. Pan7, B. Wang8, G. Chen9, K. Wang10, L. Jiang11, Y. Hu12, J. Shi13, A. Hui14, Y. Zhou15, Z. Wu16, J. Sun16, Y. Tan16, X. Xiang16, Y. Wu17

Author affiliations

  • 1 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN
  • 2 Department Of Respiratory Medicine, The First Affiliated Hospital, Zhejiang University, 310003 - Hangzhou/CN
  • 3 Department Of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, 450052 - Zhengzhou/CN
  • 4 Department Of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, 471003 - Luoyang/CN
  • 5 Department Of Oncology, Jilin Cancer Hospital, 130000 - Changchun/CN
  • 6 Department Of Thoracic Oncology, Zhejiang Cancer Hospital, 310015 - Hangzhou/CN
  • 7 Department Of Medical Oncology, Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, 310016 - Hangzhou/CN
  • 8 Department Of Thoracic Oncology,, The second affiliated hospital of xuzhou medical university, 221002 - Xuzhou/CN
  • 9 Department Of Drug Clinical Trials, Cancer Hospital Affiliated to Harbin Medical University,, 150084 - Heilongjiang/CN
  • 10 Department Of Respiratory And Critical Care Medicine, West China Hospital, Sichuan University, 610041 - Chengdu/CN
  • 11 Department Of Respiratory Medicine, Shanghai Chest Hospital Shanghai jiaotong University, 200030 - Shanghai/CN
  • 12 Department Of Thoracic Oncology, Hubei Cancer Hospital, 430079 - Wuhan/CN
  • 13 Department Of Medical Oncology, LinYi Cancer Hospital, 276002 - Linyi/CN
  • 14 Fosun Pharma Usa, Inc., Fosun Pharma USA, Inc., 02421 - Massachusetts/US
  • 15 Wanbang Biopharmaceuticals, Wanbang Biopharmaceuticals, 221004 - Jiangsu/CN
  • 16 Beijing Fosun Pharmaceutical Research And Development Co., Ltd., Beijing Fosun Pharmaceutical Research and Development Co., Ltd., 200233 - Shanghai/CN
  • 17 Department Of Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 510000 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 392P

Background

ROS1 fusions (ROS1+) are enriched in 1-2% of non-small cell lung cancer (NSCLC) cases. SAF-189s is a novel, next-generation ALK/ROS1 inhibitor which overcomes multiple resistance mutations. We explored the efficacy and safety of SAF-189s in phase (Ph) 2 study in patients (pts) with ROS1 fusion NSCLC, with or without ROS1 inhibitor treatment.

Methods

This multicenter, single-arm, open-label, Ph2 study enrolled Chinese patients with advanced ROS1+ NSCLC. The study included 2 cohorts: ROS1 inhibitor (ROS1i)-naïve or crizotinib-pretreated pts in a Ph2a cohort receiving SAF-189s with dose escalation (80, 120, 160 and 210 mg doses QD), and ROS1i-naïve pts alone in a Ph2b cohort receiving 160 mg QD. The primary endpoint was Independent Review Committee (IRC)-assessed overall response rate (ORR).

Results

Between Dec 12, 2021 and Mar 25, 2022, 48 and 56 pts were enrolled in the Ph2a and 2b cohorts, respectively. IRC-confirmed ORR in ROS1i-naïve pts were 94.1% and 80.4% and DCR were 94.1% and 96.4% in pts in Ph2a and Ph2b respectively. Notably, confirmed ORRs and DCRs were similar in pts with and without brain metastasis (Table). Median PFS was 16.5 mo in Ph 2a and not reached in Ph 2b. In crizotinib-pretreated pts in Ph2a, confirmed ORR was 40% and median PFS was 5.5 mo. The majority of treatment-related adverse events (TRAEs) were grade 1 or 2. Grade ≥3 TRAEs were observed in 29.2% and 21.4% of pts in the two cohorts, respectively. Only one pt experienced a grade 4 TRAE in 210 mg dosage of Ph2a. Treatment related SAEs were reported in 10.4% and 8.9% of pts, respectively. No treatment-related deaths were reported.

Conclusions

These findings demonstrate the promising clinical activity and a tolerable toxicity profile of SAF-189s in pts with advanced ROS1+ NSCLC, with or without crizotinib treatment. Clinical trial identification NCT04237805.

Clinical trial identification

NCT04237805.

Editorial acknowledgement

Editorial assistance was provided by Jacqi Pan of Parexel, and funded by Fosun Pharma.

Legal entity responsible for the study

Wanbang Biopharmaceuticals.

Funding

Wanbang Biopharmaceuticals.

Disclosure

Y. Wu: Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: BMS, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.